Cargando…
Which Vitamin D in CKD-MBD? The Time of Burning Questions
Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749554/ https://www.ncbi.nlm.nih.gov/pubmed/23991423 http://dx.doi.org/10.1155/2013/864012 |
_version_ | 1782477020172648448 |
---|---|
author | Galassi, Andrea Bellasi, Antonio Auricchio, Sara Papagni, Sergio Cozzolino, Mario |
author_facet | Galassi, Andrea Bellasi, Antonio Auricchio, Sara Papagni, Sergio Cozzolino, Mario |
author_sort | Galassi, Andrea |
collection | PubMed |
description | Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus calcimimetic centered regimens to control CKD-MBD. The present review arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA versus a calcimimetic based regimen in CKD-MBD patients. |
format | Online Article Text |
id | pubmed-3749554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37495542013-08-29 Which Vitamin D in CKD-MBD? The Time of Burning Questions Galassi, Andrea Bellasi, Antonio Auricchio, Sara Papagni, Sergio Cozzolino, Mario Biomed Res Int Review Article Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus calcimimetic centered regimens to control CKD-MBD. The present review arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA versus a calcimimetic based regimen in CKD-MBD patients. Hindawi Publishing Corporation 2013 2013-08-07 /pmc/articles/PMC3749554/ /pubmed/23991423 http://dx.doi.org/10.1155/2013/864012 Text en Copyright © 2013 Andrea Galassi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Galassi, Andrea Bellasi, Antonio Auricchio, Sara Papagni, Sergio Cozzolino, Mario Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title | Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title_full | Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title_fullStr | Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title_full_unstemmed | Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title_short | Which Vitamin D in CKD-MBD? The Time of Burning Questions |
title_sort | which vitamin d in ckd-mbd? the time of burning questions |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749554/ https://www.ncbi.nlm.nih.gov/pubmed/23991423 http://dx.doi.org/10.1155/2013/864012 |
work_keys_str_mv | AT galassiandrea whichvitamindinckdmbdthetimeofburningquestions AT bellasiantonio whichvitamindinckdmbdthetimeofburningquestions AT auricchiosara whichvitamindinckdmbdthetimeofburningquestions AT papagnisergio whichvitamindinckdmbdthetimeofburningquestions AT cozzolinomario whichvitamindinckdmbdthetimeofburningquestions |